Contributions of DMF_Dermot

Contributions by DMF_Dermot, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 5,312 edits includes activity predating the current log.

1. 18:00, 26 Jul 2026 (diff | hist) Asymchem Laboratories 10,289 +1,301 expand the product-scope row in the infobox
2. 10:15, 24 May 2026 (diff | hist) Talk:ISO 9001 537 +146 /* Accredited versus unaccredited bodies */ new section
3. 11:42, 13 Apr 2026 (diff | hist) Research use only 7,990 ±0 add the customs-detention point with its source
4. 09:50, 17 Mar 2026 (diff | hist) Talk:Drug master file 400 +134 /* A filing is not an approval */ new section
5. 10:42, 16 Mar 2026 (diff | hist) Orforglipron 5,647 ±0 give the isoelectric point with the method it was determined by
6. 17:36, 11 Mar 2026 (diff | hist) TRIUMPH trial programme 4,703 ±0 add the randomisation ratio
7. 07:53, 9 Feb 2026 (diff | hist) Good manufacturing practice 5,123 ±0 add the year the guidance was issued
8. 14:27, 25 Nov 2025 (diff | hist) Tianjin Finder Chemical 13,969 +220 add short description
9. 23:35, 21 Nov 2025 (diff | hist) Wuhan Wansheng Biotechnology 15,849 ±0 m add the minimum order quantity for custom synthesis
10. 15:03, 3 Nov 2025 (diff | hist) Regulatory status by jurisdiction 4,444 ±0 add the year the guidance was issued
11. 03:00, 1 Nov 2025 (diff | hist) Drug master file 4,325 ±0 m state that research-use-only labelling is a commercial category, not an approval
12. 10:35, 19 Sep 2025 (diff | hist) Body composition assessment 5,029 +128 m add category for laboratory medicine
13. 08:19, 7 Sep 2025 (diff | hist) Dulaglutide 5,490 ±0 clarify that the peptide backbone is acylated rather than PEGylated
14. 19:56, 5 Jun 2025 (diff | hist) Nantong Guangyuan Chemical 10,618 +271 correct the other-designations row — those are trading variants, not subsidiaries
15. 16:18, 11 May 2025 (diff | hist) LEADER trial 3,566 +29 rm the cross-trial comparison; the populations are not comparable
16. 10:16, 25 Apr 2025 (diff | hist) LEADER trial 3,537 ±0 m the percentage quoted was placebo-adjusted; label it
17. 13:25, 20 Apr 2025 (diff | hist) Incretin effect 5,768 ±0 de-orphan
18. 00:34, 10 Mar 2025 (diff | hist) STEP trial programme 4,357 ±0 add the run-in period, which changes how the baseline reads
19. 15:25, 27 Feb 2025 (diff | hist) Regulatory status by jurisdiction 3,277 +556 m add the note that this wiki does not give legal advice
20. 08:16, 5 Feb 2025 (diff | hist) Talk:Research use only 959 +122 /* "Not approved" versus "unapproved" */ reply
21. 14:12, 20 Jan 2025 (diff | hist) Research use only 6,662 +21 split overlong sentence
22. 23:59, 12 Oct 2024 (diff | hist) Research use only 3,726 +199 m typo
23. 04:33, 5 Sep 2024 (diff | hist) Liraglutide 2,493 ±0 correct the dose ladder — the maintenance dose is not the maximum dose
24. 09:00, 7 Aug 2024 (diff | hist) Lot traceability 2,004 +615 add the laboratory accreditation status, or say plainly that it is not stated